Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02644122 · ClinicalTrials.gov registry record · Phase 2
SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes
A Phase 2 study, sponsored by Ezra Cohen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02644122: Clinical Trial Phase 2 study, sponsored by Ezra Cohen.
NCT02644122 is a Phase 2 study that was terminated before completion, run by Ezra Cohen. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02644122, a Phase 2 study, was terminated before completion, sponsored by Ezra Cohen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to test the good and bad effects of an experimental drug called SF1126. This drug is being tested in patients whose cancer has not been controlled by available standard therapies and who have certain genes in their tumor. SF1126 is a drug that inhibits a cell protein called phosphatidyl inositol 3 kinase (PI3K). PI3K is part of signaling pathway that tells cancer cells to grow, survive, invade and metastasize. PI3K also has an important role in the development of blood vessels that are required to support tumor growth. SF1126 is being developed by SignalRx Pharmaceuticals, Inc. It is considered an experimental drug because it is not approved by the FDA for any disease treatment.
Primary Outcome
best response of PR or CR observed within 6 months of enrollment
Interventions
- DRUG SF1126
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-11 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Why NCT02644122 stopped before completion
NCT02644122 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which SF1126 is the first listed.
NCT02644122 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02644122 about?
NCT02644122 is a clinical study titled "SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes". The purpose of this study is to test the good and bad effects of an experimental drug called SF1126. This drug is being tested in patients whose cancer has not been controlled by available standard therapies and who have certain genes in their tumor. SF1126 is a drug that inhibits a cell protein ca...
What is the current status of trial NCT02644122?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2016-11. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02644122?
The interventions under investigation include: SF1126 (DRUG).
Who is sponsoring clinical trial NCT02644122?
This trial is sponsored by Ezra Cohen, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02644122's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia